Related Subjects:
|Upper Gastrointestinal Bleed
|Oesophageal Variceal Bleeding
|Dieulafoy Lesion
|Mallory-Weiss Tear
|Gastric Cancer
|Peptic Ulcer Disease
|Oesophagogastroduodenoscopy (OGD/EGD)
|Hereditary Haemorrhagic Telangiectasia
|Hypovolaemic or Haemorrhagic Shock
π Proximal gastric tumours (around the oesophagogastric junction, OGJ) are rising in incidence, while distal stomach cancers are declining.
π½οΈ Gastric cancer remains a major global cause of mortality despite falling prevalence in Western countries.
π About
- Most gastric cancers are adenocarcinomas arising from the mucosa.
- 6th most common cancer in the UK π¬π§, with poor 5-year survival (~10β20%).
- Peak incidence in older adults; β:β β 2:1.
π¬ Histological Types
- Adenocarcinoma (90β95%) β intestinal vs diffuse types (Lauren classification).
- Lymphoma β MALT type, often linked to chronic H. pylori infection.
- GIST β mesenchymal tumours; KIT/CD117 positive.
- Neuroendocrine tumours β rare, from enteroendocrine cells.
π§ͺ Pathology
- Gross appearance: ulcerating, polypoid, or infiltrative.
- Linitis plastica: diffuse infiltration β rigid βleather bottleβ stomach (poor prognosis).
- Spread routes:
- Direct β pancreas, colon, liver.
- Lymphatic β perigastric, celiac, Virchowβs node (L supraclavicular).
- Haematogenous β liver, lung.
- Transcoelomic β ovaries (Krukenberg tumour).
π Epidemiology
- Highest in Japan π―π΅, Korea, Chile, Eastern Europe.
- Western countries: β distal cancers (due to refrigeration, less salt-preserved food, β H. pylori).
- β proximal/OGJ cancers linked to obesity + reflux disease.
β οΈ Risk Factors
- π¦ H. pylori β chronic gastritis β metaplasia β carcinoma.
- π₯ Diet: high salt, smoked/pickled foods; low fruit/veg intake.
- π¬ Smoking β doubles risk.
- π¨βπ©βπ§ Family/genetic: CDH1 mutation (hereditary diffuse gastric cancer).
- π₯ Chronic gastritis & atrophy: autoimmune gastritis, pernicious anaemia.
- π΅ Age & sex: elderly, more common in men.
π©Ί Clinical Features
- Dyspepsia, early satiety, epigastric pain/discomfort.
- Anorexia, weight loss, fatigue.
- Vomiting β esp. with gastric outlet obstruction.
- GI bleeding: haematemesis or melaena.
- Advanced signs:
- Virchowβs node (L supraclavicular).
- Sister Mary Joseph nodule (umbilical deposit).
- Hepatic mets β jaundice, ascites.
- Palpable epigastric mass.
π Investigations
- OGD + biopsy: diagnostic gold standard.
- Histology: confirms subtype (adenocarcinoma vs lymphoma, etc).
- Staging: CT chest/abdomen/pelvis, PET, endoscopic US.
- Bloods: FBC (anaemia), LFTs, U&E, tumour markers (CEA, CA19-9 β not diagnostic).
π Complications
- Iron-deficiency anaemia (chronic bleeding).
- Gastric outlet obstruction β persistent vomiting + alkalosis.
- Metastatic disease (liver, peritoneum, ovary).
- Post-gastrectomy: B12 deficiency, dumping syndrome.
π οΈ Management
- Curative intent:
- Total gastrectomy (proximal/OGJ tumours).
- Subtotal distal gastrectomy (antral tumours).
- Usually with D2 lymphadenectomy.
- Chemo: peri-operative regimens (MAGIC β ECF; modern = FLOT).
- Palliative: stenting, gastrojejunostomy, systemic chemo.
- Lymphoma: often responds to H. pylori eradication.
π Prognosis
- Japan (screening) β early detection, 5-yr survival up to 90%.
- UK/West β late diagnosis, 5-yr survival ~20%.
- Worse in diffuse type, linitis plastica, and metastatic disease.
π Teaching Commentary
π©Ί Exam pearls:
β Virchowβs node + weight loss β think gastric cancer.
β Linitis plastica = classic buzzword (βleather bottleβ).
β Krukenberg tumour = ovarian mets with signet ring cells.
π‘ UK vs Japan: No population screening in UK β late diagnosis explains poor outcomes.
In OSCEs, always mention OGD with biopsy as the diagnostic test and multidisciplinary team approach for management.